Health Condition 1: L80- Vitiligo
Conditions
Interventions
Intervention1: Topical Bimatoprost 0.03% solution: Bimatoprost is a synthetic prostamide F2a analog (prostaglandin-ethanolamides) . Bimatoprost is used topically in eye drops to control the progressio
Sponsors
INDIRA GANDHI INSTITUTE OF MEDICAL SCIENCES
Eligibility
Inclusion criteria
Inclusion criteria: Patients with stable vitiligo(no progress of lesion and or development of new lesion during past 6 months) Size of lesion should be less than 1% of body surface area Less than or equal to 5 patches. Patients on other treatment of vitiligo will be included only after wash out period of 1 week for topical and systemic drugs and 4 weeks for phototherapy
Exclusion criteria
Exclusion criteria: a)Patients with lesion more than 1% of body surface area b) Number of lesion equal or more than 6 c)Periocular lesion d)Active infections e) Allergic reaction to Bimatoprost or /Tacrolimus f)Pregnancy and lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change of Vetiligo Extent Tensity Index(VETI) score from baseline over 3 monthsTimepoint: baseline (before administration of medicines) and every 4 weekly upto 3 months of starting of intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1 change of vitiligo surface area from baseline over a peroid of 3 months 2 Repigmentation grade after 3 months of intervention 3 Repigmentation type after 3 months of intervention 4 patient satisfaction by visual analog scale after intervention 5 adverse events Timepoint: Base line then 4 weekly for 3 months | — |
Countries
India
Contacts
Public ContactDr Mukesh Kumar
INDIRA GANDHI INSTITUTE OF MEDICAL SCIENCES SHEIKHPURA PATNA 14
Outcome results
None listed